We identified BRAF mutations in 21/74 (28%) patients, NRAS mutations in 4/74 (5.4%) patients, NF1 mutations in 1/74 (1.4%) patients and GNAQ mutations in 1/74 (uveal melanoma) (1.4%) patients, as well as BRAF/NRAS (1/74; 1.4%) and GNAQ/NF1 (1/74; 1.4%) double mutations (Figure 4C). Here, NRAS is linked to uveal melanoma.